Is Novo Nordisk (NVO) A Great Investment Choice?

Saturna Capital, an investment management firm, published its “Amana Funds” fourth-quarter 2021 investor letter – a copy of which can be downloaded here. For the fourth quarter of 2021, the Amana Income Fund Investor Shares returned 13.76% and the Institutional Shares returned 13.85%. The Amana Growth Fund sprinted to a strong finish in the fourth quarter, wrapping up an outstanding year by any measure. For the three months ended December 31, 2021, the Amana Growth Fund Investor Shares returned 14.41%, significantly outpacing the 6.91% Morningstar “Large Growth” category return, as well as the 11.03% return of the S&P 500. For the 2021 calendar year, Amana Developing World Fund Investor Shares returned 7.31% versus -2.54% for the MSCI Emerging Markets Index. Spare some time to check the fund’s top 5 holdings to have a clue about their top bets for 2022.

Saturna Capital Amana Funds, in its Q4 2021 investor letter, mentioned Novo Nordisk A/S (NYSE: NVO) and discussed its stance on the firm. Founded in 1923, Novo Nordisk A/S is a Bagsværd, Denmark-based multinational pharmaceutical company with a $240.7 billion market capitalization, and is currently spearheaded by its CEO, Lars Fruergaard Jørgensen. NVO delivered a -8.65% return since the beginning of the year, while its 12-month returns are up by 42.63%. The stock closed at $102.31 per share on March 08, 2022.

Here is what Saturna Capital Amana Funds has to say about Novo Nordisk A/S in its Q4 2021 investor letter:

“Given market strength, every sector provided positive returns during the quarter, led by Technology. Hardware and semiconductors were the primary contributors, although software performed better in terms of stock selection. Our Health Care investments in pharmaceuticals, particularly the diabetes duo of Eli Lilly and Novo Nordisk, performed well but medical specialties lagged.”

Photo by National Cancer Institute on Unsplash

Our calculations show that Novo Nordisk A/S (NYSE: NVO) failed to obtain a mark on our list of the 30 Most Popular Stocks Among Hedge Funds. NVO was in 28 hedge fund portfolios at the end of the fourth quarter of 2021, compared to 27 funds in the previous quarter. Novo Nordisk A/S (NYSE: NVO) delivered a 42.63% return in the past 3 months.

In December 2021, we also shared another hedge fund’s views on NVO in another article. You can find other letters from hedge funds and prominent investors on our hedge fund investor letters 2021 Q4 page.

Disclosure: None. This article is originally published at Insider Monkey.